Invasive haemodynamic measurements, natriuretic peptides assays and echocardiographic data
| All | AL | TTR | Other | |
| Right h eart c atheteri ation | n = 50 | n = 31 | n = 17 | n = 2 |
| CO, L/min | 4±1 | 4.1±1.2 | 3.9±0.7 | 3±1.4 |
| CI, L/min/m2 | 2.2±0.6 | 2.3±0.6 | 2.2±0.4 | 2.1±0.9 |
| Systolic PAP | 40±14 | 39±13 | 43±15 | 27±4 |
| Mean PAP | 25±8 | 24±9 | 26±8 | 17±3 |
| PCWP | 18±8 | 17±8 | 19±6 | 9±1 |
| Natriuretic peptides | n=48 | n=30 | n=16 | n=2 |
| BNP | 1000 (243–1477) | 858 (227–1477) | 721 (252–1255) | 4798 |
| NT-proBNP | 10 106 (2935–13 348) | 13 855 (3315–18 846) | 3346 (2587–3496) | 3456 |
| Echocardiography | n=43 | n=27 | n=15 | n=1 |
| LV septum, mm | 19±2 | 20±2 | 19±5 | 15±7 |
| LV posterior, mm | 20±2 | 21±3 | 19±6 | 10±1 |
| LVEDD, mm | 51±5 | 55±7 | 43±10 | 50±14 |
| LV mass (Penn) | 345±162 | 299±114 | 441±210 | 297±98 |
| LV mass (ASE) | 287±130 | 250±91 | 365±169 | 248±78 |
| LVEDV, mL | 91±34 | 89±32 | 95±40 | 95±22 |
| LVEF, % | 51±13 | 50±11 | 54±14 | 38±28 |
| GLS, % | −10±4 | −10±4 | −9±4 | −11 |
| LA volume, mL | 47±16 | 47±17 | 46±14 | 41±13 |
| E velocity, cm/s | 92±27 | 90±29 | 95±23 | 87±2 |
| DT, ms | 174±59 | 167±58 | 176±44 | 257±138 |
| E/A | 1.8±0.9 | 1.8±0.9 | 1.8±0.8 | 0.5±0.7 |
| Ea lateral, cm/s | 5±2 | 5±2 | 5±2 | 6±1 |
| E/Ea lateral | 18±7 | 17±7 | 19±8 | 22±1 |
ASE, American Society of Echocardiography;BNP, brain natriuretic peptide;CI, cardiac index;CO, cardiac output;DT, deceleration time;E/A, ratio of early (E) and late (A) diastolic mitral inflow velocity; Ea, early lateral mitral annular diastolic velocity; GLS, global longitudinal strain;LA, left atrial;LV, left ventricular;LVEDD, left ventricular end-diastolic diameter;LVEDV, left ventricular end-diastolic volume;LVEF, left ventricular ejection fraction;NT-proBNP, N-terminal pro-hormone brain natriuretic peptide;PAP, pulmonary arterial pressure;PCWP, pulmonary capillary wedge pressure; TTR, transthyretin amyloidosis.